Propiverine


Concise Prescribing Info
Indications/Uses
Urinary incontinence, urgency and frequency in neurogenic bladder disorders and in idiopathic detrusor instability.
Dosage/Direction for Use
Adult : PO As conventional tab: 15 mg bid or tid, up to 4 times/day if needed. Max: 60 mg/day. As modified-release cap: 30 mg once daily.
Dosage Details
Oral
Idiopathic detrusor instability, Urinary incontinence, urgency and frequency
Adult: As conventional tab: 15 mg bid or tid, increase to 4 times daily if required. Max: 60 mg daily. As modified-release cap: 30 mg once daily.
Special Patient Group
Patients receiving potent FMO inhibitors in combination w/ potent CYP 3A4/5 inhibitors: Initially, 15 mg daily.
Hepatic Impairment
Moderate to severe: Contraindicated
Administration
May be taken with or without food.
Contraindications
Obstruction of bowel, significant bladder obstruction, myasthenia gravis, intestinal atony, severe ulcerative colitis, toxic megacolon, uncontrolled angle-closure glaucoma, tachyarrhythmias. Moderate to severe hepatic impairment. Pregnancy and lactation.
Special Precautions
Patient w/ autonomic neuropathy and those who are susceptible to angle-closure glaucoma. May exacerbate severe CHF (NYHA IV), cardiac arrhythmia, tachycardia, hiatus hernia w/ reflux oesophagitis, prostatic hyperplasia. Patients receiving potent flavin-containing monooxygenase (FMO) inhibitors (e.g. methimazole) in combination w/ potent CYP 3A4/5 inhibitors. Hepatic and renal impairment.
Adverse Reactions
Hypotension, drowsiness, headache, dizziness, tremor, dysgeusia, blurred vision, palpitation, dry mouth, constipation, abdominal pain, dyspepsia, nausea, vomiting, flushing, urinary retention, fatigue.
Patient Counseling Information
This drug may cause drowsiness and blurred vision, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor liver enzyme values in long-term therapy.
Overdosage
Symptoms: Restlessness, dizziness, vertigo, speech and vision disorder, muscle weakness, severe dryness of mucosa, tachycardia and urinary retention. Management: Symptomatic and supportive treatment. Perform gastric lavage using an oiled tube.
Drug Interactions
Reduced BP when used w/ isoniazid. Drowsiness may be enhanced by drugs w/ CNS depressant properties. May decrease the effect of prokinetics (e.g. metoclopramide). Decreased effect when used w/ cholinergic drugs. Increased effect when used w/ TCAs, tranquilisers, anticholinergics, amantadine, neuroleptics and β-adrenoceptor agonists.
Action
Description: Propivexine inhibits Ca influx and modulates intracellular Ca in urinary bladder smooth cells causing musculotropic spasmolysis. It also inhibits the efferent connection of the nervus pelvicus due to anticholinergic action.
Pharmacokinetics:
Absorption: Nearly completely absorbed from the GI tract. Time to peak plasma concentration: Approx 2.3 hr. Bioavailability: Approx 41%.
Distribution: Plasma protein binding: Approx 90% (propiverine); 60% (N-oxide metabolite).
Metabolism: Undergoes extensive first-pass metabolism. Metabolised by intestinal and hepatic enzymes.
Excretion: Via urine, bile and faeces. Elimination half-life: Approx 20 hr.
Storage
Store below 25°C.
ATC Classification
G04BD06 - propiverine ; Belongs to the class of urinary antispasmodics.
References
Anon. Propiverine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/07/2016.

Buckingham R (ed). Propiverine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/07/2016.

Joint Formulary Committee. Propiverine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/07/2016.

Disclaimer: This information is independently developed by MIMS based on Propiverine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in